-
Something wrong with this record ?
Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome
K. Sloupenska, B. Koubkova, P. Horak, B. Hutyrova, M. Racansky, J. Mares, M. Miklusova, J. Schovanek, J. Zapletalova, M. Raska, M. Krupka
Status not-indexed Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
PubMed
36836887
DOI
10.3390/life13020527
Knihovny.cz E-resources
- Publication type
- Journal Article MeSH
Most patients suffering from Lyme disease are effectively treated with antibiotics. In some patients, however, problems persist for a long time despite appropriate therapy. The term post-treatment Lyme disease syndrome (PTLDS) is currently used for this condition in scientific literature. The pathogenesis is still not precisely known, but the involvement of immunopathological mechanisms is assumed. In our study, we analyzed the presence of autoantibodies including myositis-specific (MSA) and myositis-associated autoantibodies (MAA) in patients with laboratory proven history of Lyme disease and with clinical symptoms of PTLDS. A total of 59 patients meeting the criteria for PTLDS were enrolled in this study. The control group consisted of 40 patients undergoing differential diagnosis of neurological disorders without clinical and/or laboratory-proven history of Lyme disease. The presence of autoantibodies was determined by immunoblot methods and positive samples were further tested for serum creatine kinase (CK) and myoglobin levels. The presence of myositis autoantibodies was detected in 18 subjects with suspected PTLDS (30.5%), but only in 5% of control subjects exhibiting no evidence of Lyme disease history. The difference was statistically significant (p = 0.002). The subsequent biochemical analysis of muscle-damage markers in positive subjects found a mild elevation in six MSA/MAA-positive PTLDS patients. The study detected raised MSA/MAA autoantibodies formation in the group of PTLDS patients raising the question about their involvement in the pathogenesis of this syndrome.
Department of Immunology University Hospital Olomouc Zdravotniku 248 7 779 00 Olomouc Czech Republic
Department of Neurology University Hospital Olomouc Zdravotniku 248 7 779 00 Olomouc Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23002911
- 003
- CZ-PrNML
- 005
- 20240717131233.0
- 007
- ta
- 008
- 230413s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/life13020527 $2 doi
- 035 __
- $a (PubMed)36836887
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Sloupenska, Kristyna $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000200605670
- 245 10
- $a Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome / $c K. Sloupenska, B. Koubkova, P. Horak, B. Hutyrova, M. Racansky, J. Mares, M. Miklusova, J. Schovanek, J. Zapletalova, M. Raska, M. Krupka
- 520 9_
- $a Most patients suffering from Lyme disease are effectively treated with antibiotics. In some patients, however, problems persist for a long time despite appropriate therapy. The term post-treatment Lyme disease syndrome (PTLDS) is currently used for this condition in scientific literature. The pathogenesis is still not precisely known, but the involvement of immunopathological mechanisms is assumed. In our study, we analyzed the presence of autoantibodies including myositis-specific (MSA) and myositis-associated autoantibodies (MAA) in patients with laboratory proven history of Lyme disease and with clinical symptoms of PTLDS. A total of 59 patients meeting the criteria for PTLDS were enrolled in this study. The control group consisted of 40 patients undergoing differential diagnosis of neurological disorders without clinical and/or laboratory-proven history of Lyme disease. The presence of autoantibodies was determined by immunoblot methods and positive samples were further tested for serum creatine kinase (CK) and myoglobin levels. The presence of myositis autoantibodies was detected in 18 subjects with suspected PTLDS (30.5%), but only in 5% of control subjects exhibiting no evidence of Lyme disease history. The difference was statistically significant (p = 0.002). The subsequent biochemical analysis of muscle-damage markers in positive subjects found a mild elevation in six MSA/MAA-positive PTLDS patients. The study detected raised MSA/MAA autoantibodies formation in the group of PTLDS patients raising the question about their involvement in the pathogenesis of this syndrome.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Koubková, Barbora $u Department of Allergology and Clinical Immunology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic $7 xx0320139
- 700 1_
- $a Horak, Pavel $u Third Department of Internal Medicine-Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic $1 https://orcid.org/000000022394064X $7 xx0032850
- 700 1_
- $a Hutyrova, Beata $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic $u Department of Allergology and Clinical Immunology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Racansky, Mojmir $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic $u Department of Allergology and Clinical Immunology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Mares, Jan $u Department of Neurology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Miklusova, Martina $u Department of Neurology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Schovanek, Jan $u Third Department of Internal Medicine-Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Zapletalova, Jana $u Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Raska, Milan $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic $u Department of Immunology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000285727246 $7 xx0060585
- 700 1_
- $a Krupka, Michal $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000296997903 $7 xx0106791
- 773 0_
- $w MED00186366 $t Life $x 2075-1729 $g Roč. 13, č. 2 (2023)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36836887 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230413 $b ABA008
- 991 __
- $a 20240717131228 $b ABA008
- 999 __
- $a ok $b bmc $g 1922707 $s 1189118
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 13 $c 2 $e 20230215 $i 2075-1729 $m Life $n Life (Basel) $x MED00186366
- LZP __
- $a Pubmed-20230413